<DOC>
	<DOC>NCT00432770</DOC>
	<brief_summary>The purpose of this study is to establish the overall safety and tolerability of ARC1779 in healthy volunteers, and to characterize its pharmacokinetic and pharmacodynamic profile with respect to parameters of platelet function and von Willebrand Factor activity.</brief_summary>
	<brief_title>Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 in Healthy Volunteers</brief_title>
	<detailed_description>The purpose of this study is to establish the overall safety and tolerability of ARC1779 in healthy volunteers, and to characterize its pharmacokinetic and pharmacodynamic profile with respect to parameters of platelet function and von Willebrand Factor activity.</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<criteria>≥ 18 to ≤ 65 years of age Weight ≤ 110 kg Negative qualitative urine drug/alcohol test Female volunteers must be of nonchildbearing potential Male volunteers must agree to use a medically acceptable contraceptive Volunteers must be capable of understanding and complying with the protocol and must have signed the informed consent document Any clinically significant medical disorder (e.g. diabetes, hypertension, etc.) Tendency to bleed easily History of recent trauma or surgery History of gout or renal stones Clinically significant abnormal lab parameters for the following: PT INR &gt; 1.4 aPTT &gt; reference laboratory values Serum creatinine &gt; 1.3 mg/dL Platelet count of ≤ 100,000/mm3 ALT/AST &gt; 2 times ULN WBC ≤ 3000 x 109/L Hemoglobin &lt; 11 g/dL Total bilirubin &gt; 1.2 mg/dL CBT &gt; 15 min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>